Empagliflozin
This medication works by causing the kidneys to remove excess sugar from the body through urine, helping to lower blood sugar levels in type 2 diabetes. It also has proven benefits for heart and kidney health.
Masse moléculaire
450,9100 g/mol
LogP
2,00
TPSA
109,00 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Classes de médicaments
Mécanisme d'action
Selective SGLT2 inhibitor reducing renal glucose reabsorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selective SGLT2 inhibitor reducing renal glucose reabsorption.
Structure 2D
Cite this structure
Embed this structure
SMILES
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O
InChI
InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
Molecular Formula
C23H27ClO7
HBD / HBA
4 / 7
Liaisons Rotatives
6
Atomes Lourds
31
Empagliflozin and losartan can both reduce blood pressure and lower serum potassium/sodium; combined use may increase the risk of dehydration, hypotension, and electrolyte imbalance.
The combination of empagliflozin and hydrochlorothiazide can cause additive volume depletion and hypotension, and may also increase the risk of genital mycotic infections through shared glucosuria.
Combining empagliflozin with an ACE inhibitor such as ramipril can cause additive blood pressure reduction and volume depletion, increasing the risk of hypotension and acute kidney injury.
Both empagliflozin and furosemide promote natriuresis and diuresis; concurrent use can produce additive volume depletion, hypotension, and electrolyte disturbances.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
This medication works by causing the kidneys to remove excess sugar from the body through urine, helping to lower blood sugar levels in type 2 diabetes. It also has proven benefits for heart and kidney health.
Selective SGLT2 inhibitor reducing renal glucose reabsorption.
Key pharmacokinetic parameters for Empagliflozin: Half-life: 12.4 hours.
Yes, Empagliflozin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107830. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 11949646. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="empagliflozin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/empagliflozin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/empagliflozin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/empagliflozin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="empagliflozin"></drugfyi-drug>